-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
etc.
etc.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
com, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
There are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
There are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
.
.
Data source: Minet database, company announcement
On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
etc.
etc.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
com, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
There are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
There are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
.
.
Data source: Minet database, company announcement
On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's public medical institutions exceeded 600 million yuan
.
Lidocaine hydrochloride amide local anesthetics have obvious bidirectional effects of excitation and inhibition on the central nervous system, mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia, nerve conduction block,
etc.
etc.
According to data from Minet.
com, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
hospital hospital hospitalcom, in 2020, the sales of terminal lidocaine in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, and the sales in the first half of 2021 increased year-on-year.
37.
17%
.
At present, lidocaine hydrochloride dosage forms include injections, gels, patches and aerosols, among which the market share of injections is close to 80%.
There are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
enterprise enterprise enterpriseThere are more than 30 companies with production approvals for this dosage form.
has exceeded 100 million yuan
.
In terms of gel formulations, five companies, Kangye, Kangde, Jianneng, Jichuan and Zizhu, have obtained production approvals
.
In addition, only Tide has been approved for plaster, and only Xiangxue and Shanghai Pharma Xinyi have been approved for aerosol
.
Dosage forms of lidocaine hydrochloride in Chinese public medical institutions in the first half of 2021 (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
The lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical is the first approved lidocaine ophthalmic gel in China.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
The lidocaine hydrochloride ophthalmic gel is mainly used for surface anesthesia in various ophthalmic surgeries and ophthalmic examinations.
.
Before Sichuan Heyi Pharmaceutical, only the original research products of Akron Pharmaceuticals (AKORN) were approved for marketing in the world
.
Driven by the centralized procurement of intraocular lenses, the volume of ophthalmic surgeries will increase in the future, and the ophthalmic gel formulation market is expected to usher in a large volume
.
.
Data source: Minet database, company announcement
